The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver

This publication has 39 references indexed in Scilit:

• Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats
  Gut, 2006
• Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient l-amino acid-defined diet
  Biochemical and Biophysical Research Communications, 2004
• Therapeutic potential of thiazolidinediones as anticancer agents
  Expert Opinion on Investigational Drugs, 2003
• Characterizing the role of MDM2 in diethylnitrosamine induced acute liver damage and development of pre-neoplastic lesions
  Carcinogenesis, 2003
• Involvement of P21Waf1/Cip1, P27Kip1, and P18Ink4c in Troglitazone–Induced Cell–Cycle Arrest in Human Hepatoma Cell Lines
  Hepatology, 2001
• Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach
  Journal of Hepatology, 2001
• The RXR heterodimers and orphan receptors
  Cell, 1995
• ALTERED HEPATIC FOCI: Their Role in Murine Hepatocarcinogenesis
  Annual Review of Pharmacology and Toxicology, 1990
• Models of Hepatocarcinogenesis in the Rat—Contrasts and Comparisons
  CRC Critical Reviews in Toxicology, 1986
• Comparative Effects of Carcinogens on the Induction of Placental Glutathione S-Transferase-positive Liver Nodules in a Short-term Assay and of Hepatocellular Carcinomas in a Long-term Assay
  Toxicologic Pathology, 1985